News

The Seoul-based firm said that it has developed a low-cost test that can provide same-day species-level identification of the causes of infections along with antimicrobial resistance profiling results using a small volume of blood, making it suitable for testing infants in their first month of life. He said that the test could be used to inform antibiotic selection on the first day of treatment as well as help healthcare providers to determine whether to isolate the patient to reduce the spread of hospital-acquired infections, Kwon said. The sepsis test builds on the company's progress in recent years in the development of rapid, culture-free methods to identify the causes of infections and determine their antimicrobial susceptibility, Kwon said. The applications for those tests vary, though, by their uses to stratify patients by sepsis risk, determination of the type of infection, or determination of the severity of disease, and overall adoption has been slow while companies in the space build their evidence base.